Would it different from Vioxx? The challenge of the COX-2 inhibitor, Arcoxia, will begin
MSD has challenged the COX-2 inhibitor market again. However, it is analyzed that the expected result for the new challenge would not be different from the old one.
The Ministry of Food and Drug Safety, on the 24th, gave the domestic sale approval of the non-steroidal anti-inflammatory drugs-typ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
